Desensitization Strategy for an HLA-Incompatible Living Donor
A willing, available living donor and a positive crossmatch together raise a question with three genuinely different answers — treat the incompatibility with the established protocol, reach for a faster emerging one, or ask whether desensitizing against this donor at all is the right question.
Ana L. is forty-two, married nineteen years to a husband who didn't hesitate the week she started dialysis — he offered a kidney before she'd even finished explaining what dialysis was going to mean for her schedule. Her lupus nephritis, quiescent for six years now, still cost her both native kidneys before treatment fully caught up with the disease. Testing confirmed what her transplant team had warned might happen given her disease history: a calculated panel-reactive antibody of 98%, built from a combination of pregnancy and years of disease-related immune activation, and a positive crossmatch against him specifically, driven by a high-titer donor-specific antibody her body has raised against his HLA type.
Her lupus itself is not the problem in front of the team today — it has been quiet for years, confirmed by serial serology and a clean recent biopsy of her native kidney tissue before nephrectomy. The problem is narrower and more mechanical: a real antibody barrier between her and the one donor who has already offered, is medically cleared, and is sitting in the next room asking how soon this could happen. Her titer, while high, doesn't sit in the range some published desensitization cohorts have flagged as predicting poor peri-transplant outcomes even with standard treatment — a detail that matters for how urgently the team should reach past the established approach toward something faster or entirely different. It matters twice over once imlifidase enters the conversation. ConfIdeS, the pivotal randomized trial behind that drug, enrolled patients at a cPRA of 99.9% or above with a positive crossmatch against a deceased donor, and reported a mean eGFR of 51.5 against the control arm's 19.3 at twelve months. Ana is at 98%, and her donor is her husband, sitting in the next room. On the two criteria that defined the studied population she falls outside it in the same direction each time — less sensitized than the trial's patients, and holding a living offer none of them had.
She and her husband had planned this transplant around her return to a major client project this winter, a timeline that has already slipped once when the positive crossmatch came back and now hinges entirely on how quickly the team can move. Neither of them has raised the timeline pressure explicitly in clinic, but it sits underneath every question she asks about how long each option would actually take — a detail the team is trying to weigh honestly against the risk of moving too fast on an intervention still building its own track record.
Living-donor incompatibility conference
I'd start standard plasmapheresis and IVIG desensitization. It has decades of real outcome data behind it, across exactly this kind of positive-crossmatch scenario, and her titer — high, but not in the range some cohorts have flagged as predicting poor peri-transplant success — doesn't give me a strong reason to reach past an established protocol with a track record this deep.
I want imlifidase genuinely on the table before we default to the multi-week apheresis course. A single dose cleaves circulating IgG directly, which could get her transplanted within days rather than the weeks standard desensitization takes — and her donor is available right now, not on some hypothetical future date. The evidence is stronger than it was: ConfIdeS has read out, and it is a randomized trial with a large, clean effect on twelve-month graft function. I want to be equally honest about the two places it doesn't reach her. Its patients were at a cPRA of 99.9% or higher with a deceased-donor crossmatch, which is also the indication under which the drug is approved in Europe — a living husband is not the setting that was studied or licensed. And here it is still under FDA review, with a real known cost regardless: antibody levels rebound afterward, and patients typically need aggressive maintenance immunosuppression and often further IVIG to prevent early rejection once that rebound happens.
I'm not disputing the track record of standard desensitization — I'm saying the time-to-transplant difference is a real clinical variable too, not just a convenience, and it deserves to be weighed rather than assumed away by defaulting to the established option.
Before either of you commits to a way of breaking through this specific incompatibility, I want to ask whether we should be trying to break through it at all. Her husband is a willing, medically cleared donor — that's exactly the profile paired kidney exchange programs are built around. If an exchange could find her a compatible or better-matched donor elsewhere in the pool, in exchange for her husband donating to someone else's recipient, that sidesteps the entire desensitization question, its cost, and its risk, rather than choosing between two ways of paying for it.
That's not a rejection of either of your positions — it's a real, practical option that should be checked in parallel with whichever desensitization path we're leaning toward, given how much speed and cost hinge on whether a match is realistically findable in a reasonable timeframe.
Agreed: her husband registered in a paired kidney exchange program immediately, run in parallel with, not instead of, desensitization planning — standard plasmapheresis and IVIG as the default path if no exchange match materializes within a defined window. The surgeon's reframing was accepted by both other voices as the right first move, without foreclosing either desensitization option.
Not agreed: how long to let the exchange search run before committing to desensitization regardless of outcome. The immunologist wants a firm eight-week cap, arguing an extended dialysis wait carries its own real cost; the surgeon would let the search run longer given how much a better match could improve her long-term outcome, and is less willing to fix a hard deadline on a process whose timeline depends on pool composition neither of them controls.